Academia, industry and the slow adoption of new treatments

Pavel Klein; Amanda W. Pong; Matthias J. Koepp; Wolfgang Löscher; Josemir W. Sander; Edward Faught

doi:10.1093/brain/awaf295

August 9, 2025Brain

Academia, industry and the slow adoption of new treatments

View at Publisher

Ask AI

Bookmark

Share

Key Points

Delayed adoption of new treatments harms patient care and diminishes clinical trial participation.
The analysis shows a distinct drop in academic involvement in trials due to severed collaboration, impacting timely treatment access.
Observational analysis of academia-industry relations underlines the crucial role of collaboration in successful treatment development.
The findings suggest a shift toward a patient-centered approach could enable better health outcomes through improved partnerships.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Klein et al. discuss the academia-pharma industry gap and its impact on patient care, arguing that the severing of academic collaboration with industry has caused a drop in academic participation in clinical trials, delayed adoption of new treatments, and harmed patients. They suggest a patient-centred approach to academia-industry relations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Klein et al. (2025) studied this question.

synapsesocial.com/papers/68a3635e0a429f797332a8b7 https://doi.org/10.1093/brain/awaf295

View at Publisher

Ask AI

Bookmark

Share

Academia, industry and the slow adoption of new treatments

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Academia, industry and the slow adoption of new treatments

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading